| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000025016 |
| Receipt No. | R000028763 |
| Official scientific title of the study | The effect of coffee-derived mannooligosaccharides on the intestinal condition - A systematic review with meta-analysis |
| Date of disclosure of the study information | 2017/06/30 |
| Last modified on | 2017/08/03 (Ver. 4) |
| Basic information | ||
| Official scientific title of the study | The effect of coffee-derived mannooligosaccharides on the intestinal condition - A systematic review with meta-analysis | |
| Title of the study (Brief title) | A systematic review of coffee-derived mannooligosaccharides | |
| Region |
|
|
| Condition | ||
| Condition | Healthy adult volunteers or ones with a tendency for constipation | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | The objective of this review is to evaluate the effect of coffee derived-mannooligosaccharides on the intestinal condition by performing a systematic review with meta-analysis of randomized controlled trials. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | The primary outcome measures are defecation days/week, defecation frequency/week, fecal Bifidobacterium count and the occupancy rate of Bifidobacterium in the total fecal microbiota. |
| Key secondary outcomes | Defecation amount per week is a secondary outcome. |
| Base | |
| Study type | Others,meta-analysis etc |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Systematic literature search using scientific databases and registered databases for clinical trials and systematic review will be performed. Key inclusion criteria are as follows:
Participants: Healthy adults or adults with a tendency for constipation Intervention: Intake for more than 2 weeks Comparison: Placebo controll, in principle Outcome: Regulation of intestinal condition(see above outcome column) Study design: Adopt intervention study (Randomized parallel group comparison test, randomized cross over test, quasi-randomized parallel group comparison test, quasi-randomized cross over test, non-randomized parallel group comparison test) |
|||
| Key exclusion criteria | We will exclude the literature which does not meet the key inclusion criteria. | |||
| Target sample size | 0 | |||
| Research contact person | |
| Name of lead principal investigator | Shigeyoshi Fujii |
| Organization | Ajinomoto General Foods, Inc. |
| Division name | Technical Research and Development |
| Address | Sanken Building, 3-25-1, Hyakunin-cho Shinjuku-ku, Tokyo 169-0073 Japan |
| TEL | 03-5338-6713 |
| Shigeyoshi_Fujii@agf.co.jp | |
| Public contact | |
| Name of contact person | Shigeyoshi Fujii |
| Organization | Ajinomoto General Foods, Inc. |
| Division name | Technical Research and Development |
| Address | Sanken Building, 3-25-1, Hyakunin-cho Shinjuku-ku, Tokyo 169-0073 Japan |
| TEL | 03-5338-6713 |
| Homepage URL | |
| Shigeyoshi_Fujii@agf.co.jp | |
| Sponsor | |
| Institute | Ajinomoto General Foods, Inc. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Ajinomoto General Foods, Inc. |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | Review team
Mr. Kenji Yamamura, Technical Research & Development. Ajinomoto General Foods, Inc. Ms. Kaho Kanatani, Technical Research & Development, Ajinomoto General Foods, Inc. Research Collaborator Professor Hiroharu Kamioka, Faculty of Regional Environment Science, Tokyo University of Agriculture Dr. Takahiro Yoshizaki, Department of Nutritional Science, Department of Toyo University Ms. Mari Makishi, Toho University Narashino Media Center |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Published |
| URL releasing results | http://www.lifescience.co.jp/yk/yk17/july/ab1.html |
| Results | |
| Other related information | Search: We will systematically search scientific databases and registered databases for clinical trials and systematic review.
The search is performed by a specific searcher (hospital librarians, MM) who is qualified in medical information handling, and who is sophisticated in searches of clinical trials. Two authors will independently screen the literature based on key inclusion criteria. Risk of bias (quality) assessment Two authors will independently assess risk of bias based on GRADE. Agreement between the two review authors with regard to the primary outcomes and the risk of bias items will be reported as concordance rate and kappa coefficient. Indirectness, inconsistency and imprecision will be also assessed. Meta-analysis: Meta-analysis for synthetic data using Review Manager(RevMan 5.2) will be performed by TY who is highly experienced in handling meta-analysis. Estimated effect size will be expressed as standardized mean difference and 95% CI will be also calculated using randomized effect model. Forest plot will be conducted and heterogeneity will be also assessed. Publication bias will be assessed by funnel plot. Subgroup analysis: We will perform subgroup analysis for the intake amount of coffee-derived mannooligosaccharides and participants restricted to ones with a tendency for constipation. We will also conduct sub-group analysis using only randomized parallel-group trial. If the RCT includes extremely large sample size, this RCT will be excluded for the analysis. |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000028763 |